APA (7th ed.) Citation

Lee, J., Lee, M., Lee, J. Y., Bae, J., Shin, E., Lee, Y., . . . Cha, B. (2021). Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Korean Diabetes Association.

Chicago Style (17th ed.) Citation

Lee, Ji-Yeon, Minyoung Lee, Ji Young Lee, Jaehyun Bae, Eugene Shin, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, and Bong-Soo Cha. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure Through Activation of the AMPK/ SIRT1 Pathway. Korean Diabetes Association, 2021.

MLA (8th ed.) Citation

Lee, Ji-Yeon, et al. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure Through Activation of the AMPK/ SIRT1 Pathway. Korean Diabetes Association, 2021.